These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 26252565)

  • 1. Specific in vivo knockdown of protein function by intrabodies.
    Marschall AL; Dübel S; Böldicke T
    MAbs; 2015; 7(6):1010-35. PubMed ID: 26252565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances with ER Targeted Intrabodies.
    Marschall AL; Dübel S; Böldicke T
    Adv Exp Med Biol; 2016; 917():77-93. PubMed ID: 27236553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER.
    Böldicke T
    J Cell Mol Med; 2007; 11(1):54-70. PubMed ID: 17367501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?
    Marschall AL; Dübel S
    Comput Struct Biotechnol J; 2016; 14():304-8. PubMed ID: 27570612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular antibodies (intrabodies) and their therapeutic potential.
    Lo AS; Zhu Q; Marasco WA
    Handb Exp Pharmacol; 2008; (181):343-73. PubMed ID: 18071953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional knock down of VCAM1 in mice mediated by endoplasmatic reticulum retained intrabodies.
    Marschall AL; Single FN; Schlarmann K; Bosio A; Strebe N; van den Heuvel J; Frenzel A; Dübel S
    MAbs; 2014; 6(6):1394-401. PubMed ID: 25484057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional inhibition of transitory proteins by intrabody-mediated retention in the endoplasmatic reticulum.
    Böldicke T; Somplatzki S; Sergeev G; Mueller PP
    Methods; 2012 Mar; 56(3):338-50. PubMed ID: 22037249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of p75 neurotrophin receptor surface expression with intrabodies influences Bcl-xL mRNA expression and neurite outgrowth in PC12 cells.
    Zhang C; Helmsing S; Zagrebelsky M; Schirrmann T; Marschall AL; Schüngel M; Korte M; Hust M; Dübel S
    PLoS One; 2012; 7(1):e30684. PubMed ID: 22292018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody).
    Heng BC; Cao T
    Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A protein silencing switch by ligand-induced proteasome-targeting intrabodies.
    Melchionna T; Cattaneo A
    J Mol Biol; 2007 Nov; 374(3):641-54. PubMed ID: 17950312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation.
    Gennari F; Mehta S; Wang Y; St Clair Tallarico A; Palu G; Marasco WA
    J Mol Biol; 2004 Jan; 335(1):193-207. PubMed ID: 14659750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.
    Joshi SN; Butler DC; Messer A
    MAbs; 2012; 4(6):686-93. PubMed ID: 22929188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Post-translational Proteome with Intrabodies.
    Cattaneo A; Chirichella M
    Trends Biotechnol; 2019 Jun; 37(6):578-591. PubMed ID: 30577991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular antibodies and challenges facing their use as therapeutic agents.
    Lobato MN; Rabbitts TH
    Trends Mol Med; 2003 Sep; 9(9):390-6. PubMed ID: 13129705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.
    Paganetti P; Calanca V; Galli C; Stefani M; Molinari M
    J Cell Biol; 2005 Mar; 168(6):863-8. PubMed ID: 15767460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobodies Right in the Middle: Intrabodies as Toolbox to Visualize and Modulate Antigens in the Living Cell.
    Wagner TR; Rothbauer U
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33371447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.
    Jendreyko N; Popkov M; Beerli RR; Chung J; McGavern DB; Rader C; Barbas CF
    J Biol Chem; 2003 Nov; 278(48):47812-9. PubMed ID: 12947084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease.
    Sudol KL; Mastrangelo MA; Narrow WC; Frazer ME; Levites YR; Golde TE; Federoff HJ; Bowers WJ
    Mol Ther; 2009 Dec; 17(12):2031-40. PubMed ID: 19638957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Inside Job: Applications of Intracellular Single Domain Antibodies.
    Soetens E; Ballegeer M; Saelens X
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33322697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrabodies against the Polysialyltransferases ST8SiaII and ST8SiaIV inhibit Polysialylation of NCAM in rhabdomyosarcoma tumor cells.
    Somplatzki S; Mühlenhoff M; Kröger A; Gerardy-Schahn R; Böldicke T
    BMC Biotechnol; 2017 May; 17(1):42. PubMed ID: 28499450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.